Ulcerative Colitis Market

Ulcerative Colitis Market Size

The global ulcerative colitis market size was valued at USD 8 billion in 2024 and is estimated to grow at a CAGR of 5.6% from 2025 to 2034. One of the major factors contributing to the growth of this market is the rising prevalence of the disease. Urbanization, changes in diet, and environmental factors are leading to a higher incidence of inflammatory bowel diseases (IBD), such as ulcerative colitis. Along with this increase in prevalence, there is also better awareness of the disease, encouraging earlier diagnosis and treatment, which in turn boosts demand for medical therapies.

Another key driver of the market is the advancement of treatment options. The introduction of biologics (such as anti-TNF agents like infliximab and adalimumab, integrin inhibitors like vedolizumab, and IL-12/23 inhibitors like ustekinumab) has greatly expanded the range of available treatments for moderate to severe ulcerative colitis. Additionally, advances in imaging, endoscopy, and biomarkers have improved early diagnosis and treatment initiation, leading to better management of ulcerative colitis and increased use of both conventional and newer therapies. Furthermore, the growing healthcare budgets in both developed and emerging markets are driving the adoption of more advanced treatments for ulcerative colitis, thereby boosting market growth.

Ulcerative colitis is a chronic inflammatory bowel disease that causes long-lasting inflammation and ulcers (sores) in the innermost lining of the colon and rectum. The condition disrupts normal digestive processes, leading to symptoms such as diarrhea, abdominal pain, fatigue, and weight loss.

Ulcerative Colitis Market Trends

Increasing prevalence of ulcerative colitis is a key trend driving the growth of the global market.

• According to an article in Lancet, in 2023, the global prevalence of ulcerative colitis was estimated at approximately 5 million cases, highlighting the growing burden of this chronic inflammatory bowel disease. This increase is attributed to urbanization, shifts in dietary habits, and environmental factors, which are recognized contributors to the development of ulcerative colitis.
  
• The rising prevalence of ulcerative colitis has expanded the global patient pool, driving higher demand for effective treatments. Patients with mild to moderate disease benefit from oral therapies like aminosalicylates, while those with severe cases increasingly rely on biologics and JAK inhibitors.
  
• As awareness about ulcerative colitis grows among both patients and healthcare providers, earlier diagnosis and improved management strategies are becoming more common, further supporting the market's expansion.
  

Ulcerative Colitis Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on drug type, the global market is segmented into aminosalicylates, biologics, corticosteroids, Janus kinase (JAK) inhibitors, immunosuppressants, and other drug types. The aminosalicylates segment accounted for USD 2.8 billion in 2024.

• Aminosalicylates, such as mesalamine and sulfasalazine, are widely prescribed as first-line treatments for mild to moderate ulcerative colitis. Their ability to effectively reduce inflammation and maintain remission makes them a go-to option for early-stage management of the disease.
  
• This drug class is suitable for a large proportion of ulcerative colitis patients, including those with localized forms like ulcerative proctitis or left-sided colitis. This versatility in addressing different disease severities contributes to its strong market performance.
  
• Additionally, aminosalicylates are cost-effective compared to advanced therapies like biologics and JAK inhibitors, making them an accessible option for a broad range of patients, especially in regions with limited healthcare budgets.
  

Based on disease type, the ulcerative colitis market is categorized into proctosigmoiditis, ulcerative proctitis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. The proctosigmoiditis segment dominated the market and is anticipated to witness growth at 5.7% CAGR over the analysis period.

• This growth is largely driven by the high prevalence of proctosigmoiditis, a common form of ulcerative colitis affecting the rectum and sigmoid colon, which represents a significant share of ulcerative colitis cases.
  
• Additionally, the availability of targeted therapies, such aminosalicylates and corticosteroids, has proven highly effective in managing this localized disease, contributing to the segment's robust market performance.
  
• Improved diagnostic tools and greater awareness of ulcerative colitis have facilitated earlier detection and management of proctosigmoiditis, further boosting demand for treatment options.
  

Learn more about the key segments shaping this market

Download Free PDF

Based on the route of administration, the ulcerative colitis market is divided into oral and injectable. The oral segment accounted for 52.2% market share in 2024.

• The growth is driven by its convenience, broad applicability, and cost-effectiveness. Oral medications, including aminosalicylates, JAK inhibitors, and immunosuppressants, are widely preferred by patients for their ease of administration and non-invasive nature.
  
• Advancements in oral formulations, such as delayed-release and targeted delivery systems, have enhanced the efficacy and tolerability of these treatments, increasing their adoption.
  
• Additionally, they are more accessible and affordable compared to biologics and injectables. Thus, these factors are expected to drive the growth of this segment.
  

Based on distribution channel, the ulcerative colitis market is classified into hospital pharmacies, retail pharmacies and online pharmacies. In 2024, the hospital pharmacies segment held highest market share and expected to grow at 5.3% CAGR over the analysis period.

• Hospital pharmacies are critical for dispensing these complex treatments, as they offer expert drug administration and closely monitor patients for potential side effects, ensuring optimal outcomes.
  
• Additionally, the rising number of hospital admissions due to ulcerative colitis complications further boosts the demand for hospital pharmacy services. The integration of hospital pharmacies with healthcare providers enhances coordinated care and improves patient outcomes.
  
• With better access to insurance coverage and reimbursement, hospital pharmacies also make high-cost treatments more accessible to patients. These factors collectively contribute to the dominant role of hospital pharmacies in the market and its expected growth in the future.
  

Looking for region specific data?

Download Free PDF

The U.S. ulcerative colitis market was valued at USD 3 billion in 2024.

• As per National Institute of Diabetes and Digestive and Kidney Disease, around 600,000 to 900,000 people in the U.S. have ulcerative colitis. This large patient population naturally drives the demand for ulcerative colitis treatments, contributing significantly to the market's growth in the country.
  
• Another driving factor is the increasing diagnosis and awareness rates of ulcerative colitis. As awareness improves and diagnostic methods advance, more individuals seek medical attention for ulcerative colitis symptoms, leading to higher diagnosis rates and treatment uptake.
  

Germany ulcerative colitis market is predicted to grow remarkably in coming years.

• Germany has a large and growing population of individuals diagnosed with ulcerative colitis, with a high prevalence of inflammatory bowel diseases in Western Europe. As awareness of ulcerative colitis increases and more people seek medical attention for their symptoms, the demand for effective treatments is expected to rise, contributing to the overall market growth.
  
• Further, with a robust healthcare system that supports the use of advanced therapies, patients in Germany have access to the latest treatments, boosting the demand for high-cost, high-efficacy options like biologics, further driving market expansion.
  

India ulcerative colitis market is anticipated to experience lucrative growth over the forecast period.

• As awareness about ulcerative colitis rises, more people are seeking medical attention, leading to earlier diagnoses and higher treatment demand. Additionally, advancements in biologic therapies and immunosuppressants are becoming more accessible in India, boosting the market for advanced treatments.
  
• Moreover, the country’s growing aging population and increasing urbanization further contribute to the market expansion, as these factors are associated with a higher incidence of chronic diseases like ulcerative colitis.
  

Brazil's ulcerative colitis market is projected to showcase significant growth over the analysis period.

• Brazil's market is expected to grow due to increased investment in research and development, expanding clinical trials, and the introduction of innovative therapies.
  
• Additionally, improved healthcare access through the Sistema Único de Saúde (SUS) and private insurance, along with government support for biologic therapies, will boost treatment availability.
  
• Moreover, public health campaigns raising awareness contribute to early diagnosis, further driving market growth and competition for ulcerative colitis treatments.
  

Saudi Arabia ulcerative colitis market is poised to grow in coming years.

• As part of Vision 2030, Saudi Arabia is improving healthcare access and quality, focusing on reducing chronic diseases like ulcerative colitis. The government is increasing access to biologic therapies through public health programs and insurance coverage. Rising awareness about ulcerative colitis is leading to earlier diagnoses and better disease management.
  
• Significant investments in healthcare infrastructure and specialized care ensure patients have access to advanced treatments, including biologics and immunosuppressants, driving market growth.
  

Ulcerative Colitis Market Share

The market is characterized by a mix of pharmaceutical giants and biotechnology companies. These companies are continuously involved in research and development, aiming to introduce new drugs and therapies to address unmet needs in ulcerative colitis treatment. Furthermore, with increased focus on precision medicine and biologics, companies are targeting specific patient subgroups to improve treatment outcomes. Market competition is also influenced by factors such as drug pricing, access to healthcare, and regulatory approvals.

Ulcerative Colitis Market Companies

Few of the prominent players operating in the ulcerative colitis industry include:

• AbbVie
• Bausch Health Companies
• Bristol Myers Squibb
• Eli Lilly and Company
• Johnson & Johnson
• Merck
• Mitsubishi Tanabe Pharma Corporation
• Novartis
• Pfizer
• Sun Pharmaceutical Industries
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries
  

Ulcerative Colitis Industry News

• In October 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) approved VELSIPITY (etrasimod), an oral, once-daily selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis. This approval helped the company to expand its portfolio in the market and boost revenue growth.
  
• In June 2024, AbbVie announced that the U.S. Food and Drug Administration (FDA) approved SKYRIZI for adults with moderately to severely active ulcerative colitis. This approval enhances AbbVie’s position in this market, enabling the company to tap into a broader patient base and strengthen its portfolio in treating ulcerative colitis.
  

The ulcerative colitis market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Aminosalicylates
• Biologics
• Corticosteroids
• Janus kinase (JAK) inhibitors
• Immunosuppressants
• Other drug types

Market, By Disease Type

• Proctosigmoiditis
• Ulcerative proctitis
• Left-sided colitis
• Pancolitis or universal colitis
• Fulminant colitis

Market, By Route of Administration

• Oral
• Injectable

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE